A phase II trial of docetaxel in advanced non-small cell lung cancer

Anti-Cancer Drugs

Volumn 7, Issue 8, 1996, Pages 890-892

  Saarinen, A ^a   Jekunen, A ^a   Halme, M ^c   Pyrhonen S ^a   Tamminen, K ^a   Boyer, R ^b   Roubille, N ^b   Mattson, K ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b SANOFI   (France)

^c NONE

Author keywords

advanced non small cell lung cancer; docetaxel; phase II trial; single agent

Indexed keywords

DOCETAXEL;

ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALE; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0029749902     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199611000-00012     Document Type: Article

References (7)

1. Cancer Statistics. 1994. Cancer J Clin 1994: 44.
2. Francis PA, Rigas JR, Pisters KMW, Orawem JP, Woolley KJ, Heelan RT. Phase II trial of docetaxel in patients with stage III and IV non-small cell lung cancer. J Clin Oncol 1994; 12: 1232-7.
3. R) in the first and second line treatment of advanced non-small cell lung cancer. Semin Oncol 1995; 22 (suppl 4): 22-9.
4. R): current status and clinical prospects. Exp Opin Invest Drugs 1995; 4: 1185 95.
5. R: International Product monograph, 2nd edn. Rhone-Poulenc Rorer 1996: 51-5.
6. Zalcberg JR, Bishop JF, Millward MJ et al. Preliminary report of phase II trial of Docetaxel in combination with cisplatin in patients with metastatic or locally advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1994; 13: 1062.
7. Cole JT, Cralla RJ, Marques CB, Rittenberg CN. Phase I-II study of cisplatin + docetaxel in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1994; 13: 1087.